Display options
Cite
Galley G, Beurier A, Décoret G, et al. Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. ACS Med Chem Lett. 2015;7(2):192-7doi: 10.1021/acsmedchemlett.5b00449.
Galley, G., Beurier, A., Décoret, G., Goergler, A., Hutter, R., Mohr, S., Pähler, A., Schmid, P., Türck, D., Unger, R., Zbinden, K. G., Hoener, M. C., & Norcross, R. D. (2016). Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. ACS medicinal chemistry letters, 7(2), 192-7. https://doi.org/10.1021/acsmedchemlett.5b00449
Galley, Guido, et al. "Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists." ACS medicinal chemistry letters vol. 7,2 (2016): 192-7. doi: https://doi.org/10.1021/acsmedchemlett.5b00449
Galley G, Beurier A, Décoret G, Goergler A, Hutter R, Mohr S, Pähler A, Schmid P, Türck D, Unger R, Zbinden KG, Hoener MC, Norcross RD. Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. ACS Med Chem Lett. 2015 Dec 30;7(2):192-7. doi: 10.1021/acsmedchemlett.5b00449. eCollection 2016 Feb 11. PMID: 26985297; PMCID: PMC4753552.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2015 Dec 30;7(2):192-7. doi: 10.1021/acsmedchemlett.5b00449. eCollection 2016 Feb 11.

Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.

ACS medicinal chemistry letters

Guido Galley, Angélica Beurier, Guillaume Décoret, Annick Goergler, Roman Hutter, Susanne Mohr, Axel Pähler, Philipp Schmid, Dietrich Türck, Robert Unger, Katrin Groebke Zbinden, Marius C Hoener, Roger D Norcross

Affiliations

  1. Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , CH-4070 Basel, Switzerland.

PMID: 26985297 PMCID: PMC4753552 DOI: 10.1021/acsmedchemlett.5b00449

Abstract

2-Aminooxazolines were discovered as a novel structural class of TAAR1 ligands. Starting from a known adrenergic compound 1, structural modifications were made to obtain highly potent and selective TAAR1 ligands such as 12 (RO5166017), 18 (RO5256390), 36 (RO5203648), and 48 (RO5263397). These compounds exhibit drug-like physicochemical properties, have good oral bioavailability, and display in vivo activity in a variety of animal models relevant for psychiatric diseases and addiction.

Keywords: 2-aminooxazoline; SAR; TAAR1 agonist; schizophrenia

References

  1. Bioorg Med Chem Lett. 2012 Aug 15;22(16):5244-8 - PubMed
  2. Xenobiotica. 2011 Aug;41(8):652-69 - PubMed
  3. Chem Res Toxicol. 2011 Oct 17;24(10):1668-77 - PubMed
  4. Neuropharmacology. 2014 Jun;81:283-91 - PubMed
  5. Chem Biol Interact. 2011 Jun 30;192(1-2):65-71 - PubMed
  6. Biol Psychiatry. 2012 Dec 1;72(11):934-42 - PubMed
  7. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:70-5 - PubMed
  8. Mol Psychiatry. 2013 May;18(5):543-56 - PubMed
  9. Eur J Pharmacol. 2015 Sep 15;763(Pt B):136-42 - PubMed
  10. J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205 - PubMed
  11. Neuropsychopharmacology. 2014 Sep;39(10):2299-308 - PubMed
  12. Neuropsychopharmacology. 2014 Sep;39(10):2309-16 - PubMed
  13. Toxicol Lett. 1985 Feb-Mar;24(2-3):119-24 - PubMed
  14. Drug Discov Today. 2006 Feb;11(3-4):160-4 - PubMed
  15. PLoS One. 2011;6(10):e27073 - PubMed
  16. J Neurochem. 2011 Jan;116(2):164-76 - PubMed
  17. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90 - PubMed
  18. J Med Chem. 1998 Mar 26;41(7):1007-10 - PubMed
  19. Trends Pharmacol Sci. 2005 May;26(5):274-81 - PubMed
  20. Neurosci Lett. 2014 Apr 30;566:67-71 - PubMed
  21. Neuropsychopharmacology. 2012 Nov;37(12):2580-92 - PubMed

Publication Types